Use of ceramides and related products for childhood-onset eczema

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 1, 2013, Pages 12-19

  Hon, Kam L ^a   Leung, Alexander K C ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Atopic dermatitis; Ceramide; Moisturizer; Pseudoceramide

Indexed keywords

AZATHIOPRINE; CERAMIDE; CORTICOSTEROID; CYCLOSPORIN A; DERMATOLOGICAL AGENT; DOXEPIN; EMOLLIENT AGENT; HYALURONIC ACID; HYDROCORTISONE; HYDROXYZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PSEUDOCERAMIDE; TACROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ATOPIC DERMATITIS; CHILDHOOD ONSET ATOPIC DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRY SKIN; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SKIN CARE;

EID: 84874885008     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221313804004673     Document Type: Review

References (79)

1. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr 2007;54: 241-73.
2. Leung DY. Atopic dermatitis: The skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995;96(3):302-18.
3. Leung AKC, Barber KA. Managing childhood atopic dermatitis. Adv Ther 2003; 20(3):129-37.
4. Leung DY, Jain N, Leo HL. New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003;15(6):634-8.
5. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361(9352):151-60.
6. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113(5):651-7.
7. Sehra S, Tuana FM, Holbreich M, Mousdicas N, Tepper RS, Chang CH, et al. Scratching the surface: Towards understanding the pathogenesis of atopic dermatitis. Crit Rev Immunol 2008;28(1):15-43.
8. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: The impact of an educational intervention. Pediatr Dermatol 2006;23(5):428-36.
9. Williams HC. Is the prevalence of atopic dermatitis increasing?. Clin Exp Dermatol 1992;17(6):385-91.
10. Simpson EL, Hanifin JM. Atopic dermatitis. J Am Acad Dermatol 2005; 53(1):115-28.
11. Leung R, Wong G, Lau J, Ho A, Chan JK, Choy D, et al. Prevalence of asthma and allergy in Hong Kong schoolchildren: An ISAAC study. Eur Respir J 1997;10(2):354-60.
12. Leung DY, Nicklas RA, Li JT, Bernstein IL, Blessing-Moore J, Boguniewicz M, et al. Disease management of atopic dermatitis: An updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004;93(3 Suppl 2):S1-21.
13. Simpson EL. Atopic dermatitis: A review of topical treatment options. Curr Med Res Opin 2010;26(3):633-40.
14. Hon KL, Leung TF, Wong Y, Ma KC, Fok TF. Skin diseases in Chinese children at a pediatric dermatology center. Pediatr Dermatol 2004; 21(2):109-12.
15. Hon KL, Lam MC, Leung TF, Kam WY, Li MC, Ip M, et al. Clinical features associated with nasal Staphylococcus aureus colonisation in Chinese children with moderate-to-severe atopic dermatitis. Ann Acad Med Singap 2005;34(10):602-5.
16. Abramovits W. Atopic dermatitis. J Am Acad Dermatol 2005;53(1 Suppl 1):S86-S93.
17. Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004;114(3):607-11.
18. Hon KL, Leung TF, Wong K, Chow C, Chuh A, Ng P, et al. Does age or gender influence quality of life in children with atopic dermatitis? Clin Exp Dermatol 2008;33(6):705-9.
19. Ben Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol 2002;16(5):455-62.
20. Ben Gashir MA. Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood. Current Opin Allergy Clin Immunol 2003;3(5):369-73.
21. Ben Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Brit J Dermatol 2004;150(2):284-90.
22. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998;351(9117):1715-21.
23. Kristal L, Klein PA. Atopic dermatitis in infants and children. An update. Pediatr Clin North Am 2000; 47(4):877-95.
24. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 2: 44-7.
25. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994;131(3):406-16.
26. Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Brit J Dermatol 1994;131(3):397-405.
27. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Brit J Dermatol 1994;131(3):383-96.
28. Hon K, Leung TF. Seromarkers in childhood atopic dermatitis. Expert Review Dermatol 2010; 5(3): 299-314.
29. Hon KL, Wang SS, Pong H, Leung TF. Circulating immunoglobulins, leucocytes and complements are players in childhoodonset atopic eczema. Ind J Pediatr 2012; [Epub ahead of print].
30. Hanifin JM. Atopic dermatitis. J Am Acad Dermatol 1982;6(1):1-13.
31. Leung TF, Ma KC, Hon KL, Lam CW, Wan H, Li CY, et al. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediatr Allergy Immunol 2003;14(4):296-301.
32. Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 2006;118(4):866-71.
33. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38(4):441-6.
34. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 2007;39(5):650-4.
35. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin's fuller figure: A glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol 2007;127:1282-4.
36. Ching GK, Hon KL, Ng PC, Leung TF. Filaggrin null mutations in childhood atopic dermatitis among the Chinese. Int J Immunogenet 2009;36(4):251-4.
37. Enomoto H, Hirata K, Otsuka K, Kawai T, Takahashi T, Hirota T, et al. Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: A family and case-control study. J Human Genetics 2008;53(7):615-21.
38. Candi E, Schmidt R, Melino G. The cornified envelope: A model of cell death in the skin. Nat Rev Mol Cell Biol 2005;6(4):328-40.
39. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008;122(4):812-24.
40. Thulin CD, Taylor JA, Walsh KA. Microheterogeneity of human filaggrin: Analysis of a complex peptide mixture using mass spectrometry. Protein Sci 1996;5(6):1157-64.
41. Bikle DD, Chang S, Crumrine D, Elalieh H, Man MQ, Choi EH, et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol 2004;122(4):984-92.
42. O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy 2010; 40(7): 965-72.
43. Rousseau M, Bedouet L, Lati E, Gasser P, Le NK, Lopez E. Restoration of stratum corneum with nacre lipids. Comp Biochem Physiol B Biochem Mol Biol 2006;145(1):1-9.
44. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuentes L, Hogh JK, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 2010;65(7):911-8.
45. Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G. Highexpression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000;115(3):406-13.
46. Ishikawa J, Narita H, Kondo N, Hotta M, Takagi Y, Masukawa Y, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol 2010;130(10):2511-4.
47. Park KY, Kim DH, Jeong MS, Li K, Seo SJ. Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitis. J Korean Med Sci 2010; 25(5):766-71.
48. Hon KL, Wong KY, Leung TF, Chow CM, Ng PC. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, nottingham eczema severity score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008; 9(1): 45-50.
49. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. New Engl J Med 2002; 347(15): 1151-60.
50. Hon KL, Kam YW, Lam MC, Leung TF, Ng PC. CDLQI, SCORAD and NESS: Are they Correlated? Qual Life Res 2006;15:1551-8.
51. Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol 2010;35(1):22-6.
52. Hon KL, Leung TF, Wong Y, So HK, Li AM, Fok TF. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol 2005;30(4):351-4.
53. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47(2):198-208.
54. Maintz L, Novak N. Getting more and more complex: The pathophysiology of atopic eczema. Eur J Dermatol 2007;17(4):267-83.
55. Dohil MA, Eichenfield LF. A treatment approach for atopic dermatitis. Pediatric Annals 2005;34(3):201-10.
56. Lancaster W. Atopic eczema in infants and children. Community Practitioner 2009;82(7):36-7.
57. Tarr A, Iheanacho I. Should we use bath emollients for atopic eczema? BMJ 2009;339:b4273.
58. Roos TC, Geuer S, Roos S, Brost H. Recent advances in treatment strategies for atopic dermatitis. Drugs 2004;64(23):2639-66.
59. Baumer JH. Atopic eczema in children, NICE. Arch Dis Child Educ Pract Ed 2008;93(3):93-7.
60. Hon KL, Wang SS, Pong NH, Leung TF. The ideal moisturizer: A survey of parental expectations and practice in childhood-onset eczema. J Dermatolog Treat 2012; [Epub ahead of print].
61. Bissonnette R, Maari C, Provost N, Bolduc C, Nigen S, Rougier A, et al. A double-blind study of tolerance and efficacy of a new ureacontaining moisturizer in patients with atopic dermatitis. J Cosmetic Dermatol 2010; 9(1):16-21.
62. Miller DW, Koch SB, Yentzer BA, Clark AR, O'Neill JR, Fountain J, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: A randomized, controlled trial. J Drugs Dermatol 2011;10(5):531-7.
63. Chamlin SL, Frieden IJ, Fowler A, Williams M, Kao J, Sheu M, et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001;137(8):1110-2.
64. Frankel A, Sohn A, Patel RV, Lebwohl M. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic Acid emollient foam in the treatment of patients with atopic dermatitis. J Drug Dermatol 2011;10(6):666-72.
65. Loden M, Wiren K, Smerud K, Meland N, Honnas H, Mork G, et al. Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema. An open, randomized, prospective, parallel group study. Acta Dermato-Venereologica 2010; 90(6): 602-6.
66. Grimalt R, Mengeaud V, Cambazard F, Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: A randomized controlled study. Dermatology 2007; 214(1):61-7.
67. Draelos ZD. The effect of ceramide-containing skin care products on eczema resolution duration. Cutis 2008; 81(1):87-91.
68. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today 2008;44(10):751-5.
69. Hon KL, Wang SS, Lau Z, Lee HC, Lee KK, Leung TF, et al. Pseudoceramide for childhood eczema: Does it work? Hong Kong Med J 2011;17(2):132-6.
70. Lee YB, Park HJ, Kwon MJ, Jeong SK, Cho SH. Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur J Dermatol 2011;21(5):710-6.
71. Kim HJ, Park HJ, Yun JN, Jeong SK, Ahn SK, Lee SH. Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids. Allergy Asthma Immunol Res 2011;3(2):96-102.
72. Park BD, Youm JK, Jeong SK, Choi EH, Ahn SK, Lee SH. The characterization of molecular organization of multilamellar emulsions containing pseudoceramide and type III synthetic ceramide. J Invest Dermatol 2003;121(4):794-801.
73. Skold, T. Water-based delivery systems. US8029810 (2011).
74. Critchley, P., Rawlings, A.V., Scott, I.R. Synthetic pseudoceramide and cosmetic compositions thereof. US5206020 (1993).
75. Kobayashi, A., Takahashi, A., Takekoshi, Y. Preventive or remedy for atopic dermatitis. JP2011079856A2 (2011).
76. Park, B.D., Youm, J.K., Gwak, H.S., Kwon, M.J., Kim, H.M., Kang, J.S., Han, S.B. Ceramide derivatives, method for preparing the same, and therapeutic agent for treating atopic dermatitis comprising the ceramide derivative. WO2008078965 (2008) & US20080161272 (2008).
77. Grassberger, M., Hirsch, S., Mayer, F.K., Sekkat, N., Stutz, A. Pharmaceutical composition comprising a macrolide immunomodulator. WO04087202 (2004) & US20070021377 (2007).
78. Anton, S. Pharmaceutical composition comprising a macrolide immunomodulator. MX2005PA010704A (2005).
79. Stutz, A., Sekkat, N., Mayer, F.K., Grassberger, M., Hirsch, S. Pharmaceutical composition comprising a macrolide immunomodulator. CA2519958A1 (2004).